The Cruelty-Free Cosmetics Act, S 214, would ban the sale of cosmetics developed with animal testing that’s conducted four years or more after enactment, ostensibly including testing undertaken to comply with foreign regulations. The sole exemption is for animal testing that is Health Canada-authorized.
Proposed legislation to ban animal-tested cosmetics in Canada raises some of the same uncertainties that California’s Cruelty-Free Cosmetics Act did before late-stage, industry-driven amendments addressed the bill’s most problematic elements.
Introduced in December 2015 by Conservative Senator Carolyn Stewart Olsen, S 214 – also titled the Cruelty-Free Cosmetics Act...
Avista VC acquires OTC CMO Trillium; FDA deputy commissioner Jones to open CRN conference; AG1 founder steps down, COO moves up to CEO; ChromaDex hires general counsel; Ajinomoto, Shiru partner to develop sweet proteins; and change at ingredient provider LBB helm.
Brimonidine tartrate eye drops remain key sales driver among Canadian firm’s consumer health lines with 12% growth in the latest quarter. B+L expects pending launch of preservative-free line extension to sustain Lumify as a driver as generics of original formulation are approved.
Martha Stewart sells supplements on iHerb; Cheribundi partners spread the brand at Paris Games; GoodSport’s latest partner is a Bear; Herbalife-sponsored runner competes in ultramarathons; Dutch researcher joins Unicity science board; and Beacon Wellness adds sales strategy chief.
“Clear Eyes is a perfect example where we're dual-sourced and two facilities don't usually go down at the same time. This was just a quite an anomaly,” says CFO Christine Sacco, noting PCH works with more than 100 contract manufacturers.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.
